Eli Lilly is reporting promising results for the first drug to target three hormones related to weight loss—not just one or two, as current GLP-1 drugs do. In a press release, the company reported ...

Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up to 20.1 percent of their body weight on eloralintide. The once-weekly ...

Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several ...

In 2012, Novo Nordisk (NYSE:NVO) had a once-weekly version of liraglutide, the molecule behind its diabetes drug Victoza, already in early-stage human trials. The trials had confirmed the drug was ...

Retatrutide shows highest weight loss to date in trial Lilly says trial departures due to perceived excessive weight loss Retatrutide shows elevated skin-related side effects Dec 11 (Reuters) - Eli ...